TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Identification of Viruses Associated With Diseases of Unknown Cause

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Any patient with a condition or disease whose etiology is unknown.~Adequate venous access.~EXCLUSION CRITERIA:~None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Any patient with a condition or disease whose etiology is unknown.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Prolaris Value and Efficacy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed (\<= 6 months), untreated patients with histologically proven adenocarcinoma of the prostate~* Final treatment decision has not been made (that is all treatment options are feasible and none have been ruled out due to comorbidities at study entry)~* Clinically localized (no evidence on clinical or imaging studies of advanced disease)~* No hormonal therapy for treatment of prostate cancer including LHRH agonist or antagonist, anti-androgen, estrogens or exogenous androgens when applicable (use of 5-alpha reductase inhibitors is acceptable)~* Sufficient amount of tissue remains from biopsy to perform genomic testing~* Life expectance of a minimum of 10 years~* Men who completed PART 1 and were treated with radical prostatectomy (including robotic, laparoscopic, open retropubic or perineal) or receive radiation therapy or were placed on AS or WW.~Exclusion Criteria:~* Men with clinical node positive or metastatic disease~* Men with a known baseline total serum testosterone level of \<100 ng/dL prior to radiation or hormone therapy (men with unknown baseline testosterone levels will not be excluded)~* Men who previously received pelvic radiotherapy for another malignancy~* Non adenocarcinoma prostate cancer histologies

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early Stage Prostate Cancer (Type: None): Recently diagnosed treatment-naïve patients with early stage localized prostate cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study]

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Lives in the U.S.~* Able to speak, read and write in English~* Diagnosed with type 2 diabetes~* Currently treated with long-acting basal insulin analog (Lantus, Levemir, Toujeo, Basaglar, Tresiba U-100) and taking 1 injection per day~* Takes a daily dose ≤ 0.75 units/kg~* Estimated A1c ≥ 8% (based on existing Livongo data)~* Has been enrolled in Livongo for at least 12 weeks~* Uses an iPhone compatible with Insulia's compatibility matrix (iPhone 5 or higher; iOS 8 or newer)~* Willing to complete study questionnaires~* Willing to complete at-home A1c kits~* Willing to check before breakfast blood glucose at least once per day~Exclusion Criteria:~* Diagnosis of type 1 diabetes~* Currently using a long-acting basal insulin analog that is not supported by Insulia~* Currently using rapid-acting, short-acting, or intermediate-acting or premixed insulins~* Currently pregnant or planning pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Livongo-Insulia Study App Arm (Type: EXPERIMENTAL): Participants will be asked to use the Livong-Insulia Study App for the 3 month study duration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a 4mmx32G Pen Needle for Injection of Basal Insulin Doses Above 40 Units

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes mellitus~* Have been using a pen device for all diabetes or diabetes-related medications for at least one month prior to screening~* Use a pen device to self-administer greater than 40 units of Lantus, Levemir, and/or NPH in one or more single injections. For split doses, at least one of the injections must deliver more than 40 units.~* Documented hemoglobin A1c (HbA1c) from 5.5% to 9.5%, inclusive~* Self monitor blood glucose at once daily with a memory blood glucose meter, and willing do so at least twice per day for the duration of the study~* On a stable diabetes regimen (insulin and non-insulin meds, diet and exercise) for at least 1 month prior to screening~* Able to read, write and follow instructions in English~Exclusion Criteria:~* Current administration of insulin with a pump.~* Current use a syringe to inject insulin or any diabetes-related medication~* Participation in clinical study BDDC-08-011 or DBC-10-SQUIR05~* History of intravenous drug abuse.~* Current status or history of a medical condition that would contraindicate treatment with study products or other conditions which, in the opinion of the Investigator, would place the subject at risk or potentially confound interpretation of the study results (i.e., recent history of ketoacidosis, hypoglycemic unawareness, etc).~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Nano: 4mm x 32G Pen Needle (Type: EXPERIMENTAL): Subjects will use the 4mm x 32G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
- Short: 8mm x 31G Pen Needle (Type: EXPERIMENTAL): Subjects will use the 8 mm x 31G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy, adult subjects, 18 years and older~* able to swallow medication~Exclusion Criteria:~* institutionalized subjects~* history of any significant disease~* use of any prescription or OTC medications within 14 days of start of study~* received any investigational products within 30 days prior to start of study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Olanzapine Tablets 20 mg
- 2 (Type: ACTIVE_COMPARATOR): Zyprexa® Tablets 20 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Elevation of the Fetal Buttocks Prior to External Cephalic Version

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women delivering at AdventHealth Orlando campus.~2. Breech presenting part as diagnosed by bedside sonography.~3. No prior deliveries \>/= 20 weeks gestational age.~4. Pregnancy is between 37-40 weeks gestational age.~5. Live fetus.~6. Patient is \>/= age 18.~7. Patient speaks English or Spanish as primary language.~8. Patient able to understand verbal and written consent~Exclusion Criteria:~1. Non-breech presentation (cephalic, transverse, oblique).~2. More than 1 fetus.~3. Cervical dilation of \>/= 1cm.~4. Prior uterine incision.~5. Congenital uterine anomaly.~6. Body mass index more than 40 kg/m2.~7. Uterine fibroids causing soft tissue dystocia.~8. Extended fetal neck.~9. Oligohydramnios (4-quadrant amniotic fluid index \</= 5cm).~10. Spontaneous rupture of membranes.~11. Any contraindication to vaginal delivery.~12. Intrauterine growth restriction (estimated fetal weight \</= 10%ile).~13. Estimated fetal weight \> /= 5,000 grams for non-diabetic patient or \>/= 4,500 grams for patient with pre-existing or gestational diabetes, confirmed by ultrasound.~14. Fetal gastroschisis.~15. Fetal neural tube defect.~16. Severe-range preeclampsia.~17. Patient had regional anesthesia immediately prior to ECV.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: SHAM_COMPARATOR): Non-inflation of the balloon device
- Intervention (Type: EXPERIMENTAL): Inflation of the balloon device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Self-activation in Individuals With and Without Nicotine Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-45 years of age~2. Right handed~3. In good general health~4. Male or Female~5. For ND individuals: Self-reported smoking ≥ 5 combustible cigarettes per day~6. For ND individuals: Afternoon expired CO concentration of ≥ 8 ppm~7. For ND individuals: Is willing and able to abstain from smoking for a few hours~Exclusion Criteria:~1. History of chronic/significant medical condition~2. Current or past 6 month use of prescription medications for psychiatric conditions (e.g., depression, anxiety)~3. Current or past 6 month diagnosis of anxiety, bipolar disorder, depression, OCD, schizophrenia, psychosis, or personality disorder.~4. Current substance abuse or dependence or history within the last 6 months (other than nicotine for ND individuals)~5. For ND individuals: Positive drug test for anything other than marijuana~6. For ND individuals: Currently on nicotine replacement therapy~7. For ND individuals: Individuals who role their own cigarettes~8. For ND individuals: Daily cannabis use~9. For ND individuals: Consume more than 21 alcoholic drinks per week~10. For ND individuals: Use harder drugs (e.g., cocaine, methamphetamine) more than 10 times per year~11. For ND individuals: Currently taking medication that directly acts on the dopamine system (e.g., L-DOPA).~12. Inability to understand written and/or spoken English language~13. For MRI subjects: Claustrophobia or other contraindications to MRI scanning~14. For MRI subjects: If female, pregnancy as determined by urine pregnancy test on the day of MRI scanning~15. For MRI subjects: Presence of any metal in the body (e.g., implant, non-removable piercing, metal IUD)~16. For MRI subjects: Head injury resulting in loss of consciousness~17. For MRI subjects: Worked with metal (e.g., welding) or had an injury to the eye involving metal~18. For MRI subjects: Weigh more than 250 pounds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Reward-related Brain Region Feedback (Type: EXPERIMENTAL): Participants in this group will receive neurofeedback from a reward-related brain area (e.g., VTA, PFC) using EEG and/or fMRI during the experiment.
- Noise Control (Type: SHAM_COMPARATOR): Participants in this group will receive sham neurofeedback. Participants will be debriefed at the end of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for patients:~* Patients aged 45 and over~* Patients from Grade 3 'end of primary schooling minimum (scale Barbizet)~* Non-Metastatic Breast Cancer~* Adjuvant Chemotherapy: FEC, including Docetaxel Protocols~* No major cognitive impairment~* No previous neurological~* Lack of personality disorders and psychiatric disorders evolutionary~* Having signed the informed consent of study participation~Inclusion Criteria for control group:~* Women from the general population aged 45 and over, and matched in age and cultural level in patients~* Topics of Grade 3 'end of primary schooling minimum (scale Barbizet)~* No prior cancer~* No major cognitive impairment~* No previous neurological~* Lack of personality disorders and psychiatric disorders evolutionary~* Participating in the IMAP Protocol No. ID-BCR: 2007-A00414-49 or IMAP+(n° ID RCB 2011-A01493-38)(see how the study below) have signed forms no objection and consent to study participation~Exclusion Criteria:~Traduction (français \> anglais)~* Metastatic~* Cancer of the breast other than primitive~* Patients with paraneoplastic syndrome~* Patients under 45 years~* Patients whose achievement is below level 3 'end of primary schooling (scale Barbizet)~* Patients with adjuvant chemotherapy is associated with targeted therapy~* Patients who have received other cancer treatments (chemotherapy or radiotherapy brain)~* Contraindication to the implementation of an MRI (claustrophobia, metal objects in the body)~* disorders of higher functions existing in the administration of chemotherapy~* Neurologic earlier~* Pathology psychiatric evolutionary~* Refusal of participation~* Patients unable to meet the cognitive tests~* Drug use~* Heavy drinking

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- patients aged 45 and over group (Type: EXPERIMENTAL): patients aged 45 and over with breast cancer and should receive an adjuvant chemotherapy
- healthy volunteers (controls) aged 45 and over (Type: ACTIVE_COMPARATOR): healthy volunteers (controls) aged 45 and over

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
INCLUSION Criteria:~Active Duty Military Members with at least 10 years of service~Enlisted Rank~Males 35 years and older OR Females 45 years and older (please note the age difference is due to the fact that female plaque formation with calcification has been shown to lag that of males by about 10 years)~One or More of the Following Risk Factors:~Smoker - at least 5 pack years in the past 5 years (pack year = number of packs per day number of years of smoking)~Diabetic (Fasting glucose of \>125 mg/dL on two or more blood draws, or Random Blood Glucose of \>200 mg/dL on a single blood draw, or Hemoglobin A1C \>6.5%, or previous diagnosis of diabetes listed in the subject's medical record) or Pre-diabetic (Fasting glucose \>100 on two or more blood draws or Hgb A1C 5.7-6.4)~Hypertension (Systolic BP \> 140 or Diastolic BP \>90 or on blood pressure medications or diagnosis of hypertension in medical record)~Waist Circumference \> 40 inches for males or \>35 inches for females~Hyperlipidemia (LDL\>130, HDL\<40 for males, HDL \<50 for females, Triglycerides \>200, on lipid lowering medications and/or diagnosis of hyperlipidemia in medical record)~EXCLUSION Criteria:~Males \<35 years old~Women \<45 years old (please note the age difference is due to the fact that female plaque formation with calcification has been shown to lag that of males by about 10 years)~Officer Rank - officers are excluded as we are looking at the enlisted culture in the military.~History of any of the following:~Coronary Artery Disease (CAD)~Coronary Artery Bypass Grafting (CABG)~Myocardial Infarction (MI)~Percutaneous Intervention/Stent Placement (PCI)~Angina~Radiotherapy (external beam, brachytherapy, radiopharmaceutical)~Under the care of any of the following types of providers in the past 12 months (As these subjects are at greater risk of having had significant radiation exposure to the chest over the past 12 months):~Radiation/Medical Oncologist~Interventional Radiologist~Cardiologist~Cardiothoracic Surgeon~Vascular Surgeon~Females who think they may be pregnant~Pregnant females

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* No known history of diabetes~* Admission or pre-entry plasma glucose (PG) level between 140 and 400 mg/dL~* Non-critically ill and admitted to acute care medical services~* Have a body mass index greater than or equal to 18.5 kg/m\^2 and less than or equal to 45 kilograms per square meter (kg/m\^2)~Major Exclusion Criteria:~* Received any insulin/analog therapy for longer than 108 hours prior to study entry or intermediate- or long-acting insulin/analogs (neutral protamine Hagedorn, detemir, or glargine) in the 24 hours prior to randomization or any intravenous insulin therapy prior to randomization~* Laboratory evidence of diabetic ketoacidosis for patients with pre-randomization PG greater than 250 mg/dL~* Have taken any oral or injectable antihyperglycemic medications other than insulin within 3 months prior to study entry~* Have acute critical illness or are expected to require admission to an ICU or equivalent or be treated with glucocorticoid therapy during the hospital study period~* Expected hospitalization less than 24 hours post-randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sliding scale regular insulin (Type: ACTIVE_COMPARATOR): None
- Basal-bolus therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Sleep Apnea on Diabetic Foot Wound.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Types 1 or 2 or MODY diabetes with diabetic foot wound (or at risk of foot wound stage 2 and 3 (see reference PMID:18442189).~* Patients covered by social insurance~Exclusion Criteria:~* Patients with sleep apnea syndrome previously treated by positive airway pressure therapy.~* Patients previously treated by additional oxygen therapy. Patient with unstable psychiatric disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Foot-wound without SAS (Type: None): patients with diabetic foot wound(or at risk of diabetic foot wound) without sleep apnea syndrome
- Foot-wound with SAS (Type: None): patients with diabetic foot wound(or at risk of diabetic foot wound) with sleep apnea syndrome

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presenting with an ERT (i.e. rectal adenoma or rectal carcinoma Tis or staged usT1N0 on endorectal ultrasound) that can be alternately resectable by TEM or ESD~* Histology proved by a preoperative biopsy~Exclusion Criteria:~*  Palliative  excision T2/3/4 or N+~* Preoperative radiochemotherapy (down-staging)~* Metastatic cancer~* Pregnant or breast-feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transanal endoscopic microsurgery group (Type: EXPERIMENTAL): None
- endoscopic submucosal dissection group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MediGuide Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Anybody coming for CRT or EP procedure utilizing MediGuide system and tools~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRT (Type: None): Patients who are undergoing CRT implantation utilizing MediGuide system and tools
- EP (Type: None): Patients who are undergoing ablation procedures for Atrial Fibrillation, Atrial Flutter, and Ventricular Tachycardia utilizing MediGuide system and tools

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy